Joseph Merola, MD, MSc, FACR, FAAD

UT Southwestern Medical Center
Dallas, TX, United States

Joseph F. Merola, MD, MMSc is Chair of Dermatology at UT Southwestern Medical Center in Dallas, TX; he is Professor of Dermatology, Professor of Medicine and Rheumatology and Professor at the Peter O’Donnell Jr School of Public Health. He holds the Mary Kay Distinguished Chair in Dermatology. Dr. Merola is board-certified in Dermatology, Internal Medicine, and Rheumatology.

Presentation(s):

0574: Bimekizumab 3-Year Efficacy In Patients With Psoriasis And Risk Factors For Progression To Psoriatic Arthritis Or Screening Positive For Psoriatic Arthritis: Long-Term Results From Five Phase 3/3b Trials

Sunday, October 26, 2025
10:30 AM - 12:30 PM Central Time
Disclosure information not submitted.
0573: Effects of Sonelokimab, an IL-17A- and IL-17F-Inhibiting Nanobody, on Patient-Reported Symptoms and Quality of Life in Psoriatic Arthritis: Results From the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial

Sunday, October 26, 2025
10:30 AM - 12:30 PM Central Time
Disclosure information not submitted.
0555: Phase 3 Results From an Innovative Trial Design of Treating Plaque Psoriasis Involving Difficult-to-Treat, High-Impact Sites With Icotrokinra, a Targeted Oral Peptide That Selectively Inhibits the IL-23–Receptor

Sunday, October 26, 2025
10:30 AM - 12:30 PM Central Time
Disclosure information not submitted.
0875: Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-Inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)

Monday, October 27, 2025
10:30 AM - 10:45 AM Central Time
Disclosure information not submitted.
1165: Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Tumor Necrosis Factor Inhibitors

Monday, October 27, 2025
10:30 AM - 12:30 PM Central Time
Disclosure information not submitted.
2409: Cutaneous Lupus Activity Investigator’s Global Assessment―Revised (CLA-IGA-R) Content Validity: Cutaneous Lupus Erythematosus (CLE) Patient Qualitative Study

Tuesday, October 28, 2025
10:30 AM - 12:30 PM Central Time
Disclosure information not submitted.
2408: Direct Medical Cost Burden of Cutaneous Lupus Erythematosus (CLE): A Comparison with Psoriasis, Atopic Dermatitis, and a General Population

Tuesday, October 28, 2025
10:30 AM - 12:30 PM Central Time
Disclosure information not submitted.